linjc16/ctgov huggingface dataset:
Investigation of the Relationship Between Lower and Upper Extremity Selective Motor Control and Sensory Functions in Children With Spastic Cerebral Palsy

Study Overview
=================
Brief Summary
-----------------
Although spasticity, contractures and muscle weakness in children with CP are disorders that can be observed more easily and are more focused and given more importance in evaluation and treatment approaches; Inadequate or loss of selective motor control negatively affects motor functions to a greater extent. It is very important to reveal the causes and consequences of selective motor disability in children with spastic cerebral palsy, in terms of creating effective treatment plans. The number of patients to participate in the study was determined as 100. The study will be carried out in Hatay Mustafa Kemal University Research and Application Hospital, Department of Pediatrics. In our study, demographic information will be filled in, and lower extremity selective control assessment scale (SCALE) for lower extremity, upper extremity selective control scale (SCUES) for upper extremity, and sensory assessment (touch, two-point discrimination and proprioceptive sensory assessment) will be performed on the patients who accepted the study.

Official Title
-----------------
Investigation of the Relationship Between Lower and Upper Extremity Selective Motor Control and Sensory Functions in Children With Spastic Cerebral Palsy

Conditions
-----------------
Spastic Cerebral Palsy, Motor Activity, Lower Extremity Problem, Upper Extremity Problem

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Giving consent to participate in the study To be diagnosed with spastic type cerebral palsy; Being between the ages of 4-18; Being at level I-II-III according to the gross motor function classification system (GMFCS); Not having undergone Botulinum Toxin injection/lower-upper extremity surgery in the last 6 months Exclusion criteria: To be in level IV-V according to gross motor function classification system (GMFCS) Having severe mental retardation who does not understand verbal commands

Ages Eligible for Study
-----------------
Minimum Age: 4 Years
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of selective motor control function |  | 2 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The relationship between selective motor control and sensory functions |  | 3 months |
Smoking Pattern and Influencing Factors in Hospitalized Patients

Study Overview
=================
Brief Summary
-----------------
This study examines the smoking patterns and determinants of inpatients who smoke, develops tailored smoking cessation interventions based on their individual needs, and aims to enhance the effectiveness of quitting and lower the likelihood of relapse.

Detailed Description
-----------------
Smoking is a major risk factor for many chronic and acute diseases, and quitting smoking can bring significant health benefits. However, many smokers find it hard to quit or relapse after quitting. This study aims to explore the smoking behavior and influencing factors of inpatients who smoke. The survey will collect data on the demographic, clinical, psychological, and behavioral aspects of the participants, as well as their smoking history, nicotine dependence, withdrawal symptoms, confidence and motivation to quit, and perceived barriers and facilitators to quitting.

Official Title
-----------------
A Survey of Smoking Patterns and Influencing Factors Among Hospitalized Patients

Conditions
-----------------
Smoking Behaviors

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged 18 and above; smoke at least 1 cigarette daily; willing to participate in this study Exclusion Criteria: Smokers who have mental illness or cognitive impairment; Unable to complete the questionnaire survey

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Smoking cessation rate at 6 months after discharge | The number of participants who quit smoking at 6 months after discharge, verified by carbon monoxide (CO) test | 6 months after discharge | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Smoking reduction rate at 6 months after discharge | The number of participants who reduce their daily cigarette consumption by at least 50% at 6 months after discharge | 6 months after discharge | 
| Quit attempt rate during the 6-month follow-up period | The number of participants who make at least one quit attempt during the 6-month follow-up period, verified by self-report | 6 months after discharge | 
| Nicotine dependence level | The level of nicotine dependence, measured by the Fagerström Test for Nicotine Dependence (FTND) at baseline, discharge, and 6 months after discharge | Baseline, and 6 months after discharge |
Multicenter Retrospective Study of Isoflurane in Refractory and Super-Refractory Status Epilepticus

Study Overview
=================
Brief Summary
-----------------
Isoflurane might be used as anticonvulsive therapy in refractory status epilepticus. The aim of the study is to assess the efficiency of Isoflurane in this indication.

Detailed Description
-----------------
Investigators will collect in 4 ICUs the data from consecutive patients hospitalized between january 2016 and january 2023. Included patient were those treated by Isoflurane for refractory status epilepticus.

Official Title
-----------------
Multicenter Retrospective Study of Isoflurane in Refractory and Super-Refractory Status Epilepticus (I-Seizure)

Conditions
-----------------
Refractory Status Epilepticus

Intervention / Treatment
-----------------
* Drug: Isoflurane


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age > 18 years, hospitalized in ICU between 2016-01-01 and 2023-01-01, suffering refractory status epilepticus treated by inhaled Isoflurane as third anticonvulsive therapy Exclusion Criteria: post-anoxic refractory status epilepticus after cardiac arrest, withdrawal of consent for medical data use

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Main cohort<br>Adult patients with refractory status epilepticus treated by Isoflurane as third anticonvulsive therapy | Drug: Isoflurane<br>* no other intervention<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| rate of crisis control | rate of patients with crisis control or complete awakening | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Isoflurane
Evaluating Patient Experiences in Skin Care Clinical Studies

Study Overview
=================
Brief Summary
-----------------
Enrollment in clinical trials usually favors a particular demographic group. But there is limited research available to explain what study attributes affect the completion of these specific demographic groups. This trial will evaluate the safety and efficacy of new skin care products and treatments. The focus will be on tracking the rates of completion and withdrawal among these individuals. It will also try to analyze data from the perspective of different demographic groups to check for recurring trends which might yield insights for the sake of future skin care studies.

Official Title
-----------------
An Observational Study Analyzing Patient Experiences in Skin Care Clinical Trials

Conditions
-----------------
Skin Care

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is at least 18 years of age Patient is able and willing to comply with the treatment/follow-up schedule and requirements Patient must provide written informed consent Exclusion Criteria: Women who are pregnant, intend to become pregnant, or are lactating Inability to perform regular electronic reporting Participants who are vulnerable to any intervention

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Rate of patients who decide to enroll in a skin care clinical study. |  | 3 months | 
| Number of skin care study participants who remain in clinical trial until completion. |  | 12 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Skin Care
Evaluation of Tp-e Interval and Tp-e/QT Ratio in Dermatomyositis and Analysis of Their Relationship With Inflammation

Study Overview
=================
Brief Summary
-----------------
The goal of this observational study is to investigate ventricular repolarization utilizing Tp-e intervals and Tp-e/QT ratios in patients with DM. The main questions it aims to answer are: 1.Exploring the changes in ventricular repolarization parameters (QT interval, QTc interval, QTd, Tp-e interval, Tp-e/QT ratio) in patients with dermatomyositis, providing quantifiable indicators for early detection of arrhythmia in dermatomyositis patients; 2.Exploring the role of inflammation in ventricular repolarization in DM patients, providing a basis for in-depth research on the diagnosis and prevention of arrhythmia in DM patients.

Official Title
-----------------
The Third People's Hospital of Hangzhou

Conditions
-----------------
Dermatomyositis, Myocardial Repolarization, Inflammation

Intervention / Treatment
-----------------
* Other: disease


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Regardless of gender, registered residence and education level, voluntarily participate in this study and sign the informed consent form. Clinical diagnosis of Dermatomyositis. Exclusion Criteria: Previous history of heart disease (such as myocardial infarction, cardiac pacing, congenital heart disease, ischemic heart disease, etc.), chronic kidney disease, etc; Patients with other connective tissue diseases; Pregnant and lactating women. Taking drugs that affect electrocardiogram indicators, such as macrolides, quinolones, quinidine, amiodarone, antipsychotic drugs, etc. Patients with severe lack of case data.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Dermatomyositis patients<br> | Other: disease<br>* Do you have dermatomyositis<br>|
| The control group was comprised of age- and gender-matched healthy volunteers<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| QTc, Tp-e interval, and Tp-e/QT ratio were increased in DM patients. |  | November 2011 to November 2022 | 
| the Tp-e interval and Tp-e/QT ratio were positively correlated with Inflammation. |  | November 2011 to November 2022 |
Prediction of Placental Fetal Growth Restriction in High Risk Population (PoPFGR)

Study Overview
=================
Brief Summary
-----------------
This study aims to establish a multicenter cohort of FGR high-risk pregnant women, and aims to construct a combined predictive model for FGR by combining basic characteristics, medical history, early pregnancy ultrasound, and biomarkers.

Detailed Description
-----------------
Most FGR predictions are based on early pregnancy screening models for preeclampsia or mid-pregnancy screening models for Down syndrome, which have limited value. And specially clinical screening for maternal vascular malperfusion fetal growth restriction (MVM-FGR) in the general population was not recommended by most guidelines. This study aims to establish a multicenter, prospective cohort of FGR high-risk pregnant women. Baseline characteristics, and prenatal ultrasound evaluations of fetal growth, placental and maternal-fetal Doppler blood flow, and structural assessments, will be collected. Maternal serum and plasma will also be collected for biomarker testing. Fetal growth, information on pregnancy status, delivery information, and placental pathology test results will be collected. By combining medical history, ultrasound, serum, and plasma biomarkers, we will establish an combined predictive model for prediction of MVM-FGR at early pregnancy.

Official Title
-----------------
Prediction of Placental Fetal Growth Restriction in High Risk Population (PoPFGR)

Conditions
-----------------
Fetal Growth Retardation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pregnant women with gestational age of <10 weeks, maternal age between 18 and 45 years old; and with presence of at least one of FGR high risk factors: maternal age≥40；or maternal age ≤20； or maternal age≥38 and primipara; or Chronic hypertension or diabetes; or pregnancy history of FGR, preeclampsia, unknown stillbirth, or placental abruption; between Aug 2023 and Dec 2025. Exclusion Criteria: Presence of fetal genetic abnormalities or severe structural abnormalities in prenatal ultrasound or genetic testing. Presence of a serious acute or chronic illness.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Development of Fetal growth restriction | Development of Fetal growth restriction | during the pregnancy, up to an average gestational age of 40 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Birth weight | Birth weight of the neonate | the day at birth | 
| incidence of other adverse pregnancy outcomes | including miscarriage, preeclampsia, and intrauterine fetal death; | pregnancy-born after 28 days |
Evaluation of Tolerability, Efficacy and Adherence to Treatment With Wynzora Cream

Study Overview
=================
Brief Summary
-----------------
The primary objective is to assess with the PPQ questionnaire the patient preference for Wynzora compared with therapy carried out previously with Enstilar spray foam. Secondary objectives Assess satisfaction with the treatment. Assess adherence to therapy. Evaluate the impact of various clinical and demographic factors on treatment adherence. Evaluate the efficacy of Wynzora cream therapy.

Official Title
-----------------
Evaluation of Tolerability, Efficacy and Adherence to Treatment With Wynzora Cream in Patients With Psoriasis Previously Treated With Enstilar Foam.

Conditions
-----------------
Psoriasis

Intervention / Treatment
-----------------
* Other: questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients older than 18 years of age, of either sex; Patients diagnosed with mild-to-moderate psoriasis (PASI and BSA &lt;10) requiring monotherapy topical with Wynzora; Patients who have stopped treatment with Enstilar foam for any reason for at least 30 days; and Patients whose medical records are accessible and record all demographic parameters, anthropometric and clinical parameters during the treatment period Signature of written informed consent; Exclusion Criteria: Patients with palmoplantar, inverse, erythrodermic, guttate, and scalp psoriasis. Patients who are taking concomitant systemic therapies for psoriasis, such as. cyclosporine, methotrexate, acitretin, phototherapy or biologic therapies. Women who are pregnant or planning to become pregnant. Patients with disabilities or other motor problems that could complicate self-medication.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: questionnaire|PPQ, TTAQ PTCS|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| preference of wynzora cream | Percentage of patients who prefer treatment with Wynzora compared with treatment with Enstilar at week 4 of use; preference for Wynzora will be assessed by considering a score of 3 or higher on question 5 of the PPQ questionnaire. | 1 month |
Doppler Ultrasound and CT Versus Laparoscopy in Assessment of Ovarian Malignancy

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to assess validation of ultrasound (± Doppler) parameters in the diagnosis of suspicious ovarian malignant tumors and laparoscopic assessment of these findings according to Fagotti score evaluation of suspicious malignant tumors

Detailed Description
-----------------
The aim of this study is to asses validation of ultrasound (± Doppler) parameters in the diagnosis of suspicious ovarian malignant tumors and laparoscopic assessment of these findings according to Fagotti score evaluation of suspicious malignant tumors

Official Title
-----------------
Validation of Doppler Ultrasound, CT Parameters Versus Laparoscopic Scoring in Assessment of Suspicious Ovarian Malignancy

Conditions
-----------------
Ovarian Cancer

Intervention / Treatment
-----------------
* Procedure: Laparoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all patients with clinical or radiological suspicion of ovarian cancer. at least one of clinical presentation of suspected or advanced ovarian cancer and performed ultrasound or CT or MRI that detect a pelvic mass and CA125 is more than 200 UL/ML. patients with eastern Cooperative Oncology Group status from 0 to 3. Exclusion Criteria: the women outside the age group in our study. any known malignancy at other sites. uncompliant patients who have severed uncontrolled infection or any other medical problem. any previous major surgery. patients who refuse to give an informed consent to do laparoscopy. pregnancy and its complications.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Female

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Women with suspicion of ovarian malignancy<br>Women with suspicion of ovarian malignancy depending on ultrasound, CT, MRI and CA 125 | Procedure: Laparoscopy<br>* Patients included in this study will have diagnostic laparoscopy type WOLF done after checking all above ultrasound parameters of malignant tumor. This procedure will be done under general anathesia then a verses needle will be used at umbilicus or at palmer point if the mass is large or in cases of umbilical hernia or previous abdominal or pelvic surgery, then Fagotti criteria will be assessed<br>* Other names: Laparoscopic Fagotti scoring;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fagotti score | Laparoscopic staging of suspicious ovarian mass | Al time of laparoscopy | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Ovarian cancer, Doppler, CT, Laparoscopy
New Antigens Against Glioblastoma

Study Overview
=================
Brief Summary
-----------------
In this study the investigators will select and develop potential therapeutic monoclonal antibodies (mAbs) for glioblastoma (GB). Activities include tissue microarray (TMA) to test monoclonal antibodies specificity and target distribution, selection of glioblastoma specific functional monoclonal antibodies, identification of candidate targets.

Official Title
-----------------
Identification of New Antigens Against Glioblastoma

Conditions
-----------------
Glioblastoma Multiforme

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age > 18 years; Written informed consent Exclusion Criteria: Not-availability of informed consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Validation of the tumour specificity of the identified monoclonal antibodies | Candidate monoclonal antibodies will be tested by immunohistochemistry (IHC) on sections of glioblastoma tissue and healthy counterpart. | 4 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Generate the single chain Fab antibody fragments (scFv) and then develop the Chimeric Antigen Receptor (CAR) T cells | After defining a subset of potentially highly selective  7 monoclonal antibodies, together with the  6 that showed preliminary activity in cytotoxic tests (either alone or conjugated), the investigators will perform a thorough analysis of their specificity on a TMA platform. After establishing the staining conditions, the investigators will test multiple tumor and multiple normal TMAs | 4 years |